HAEMONETICS CORP — Director's Dealing 2023

May 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2023-05-15

Reporting Person: Lingamneni Anila (EVP, Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-15	Common Stock	A	3364	—	Acquired	20807	Direct
2023-05-16	Common Stock	F	318	$89.21	Disposed	20489	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-15	Non-qualified Stock Option (Right to Buy)	$89.16	A	7602	Acquired	2030-05-15	Common Stock (7602)	Direct

Footnotes

F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3: This number includes unvested RSUs previously reported as well as 297 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 28, 2023.

F4: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.

F5: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.